Dis-Chem Pharmacies Limited (DCP) Fair Value & Analysis
Healthcare · ZA · Market cap 27.6B ZAC
Fair value as of: Jul 19, 2026
From 26 valuation models · updated 23 days ago
Share price −6.9% over the past month.
A solid business, but screening 25% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (R30.01). The favourable scenario is already priced in.
- Solid but not exceptional quality (55/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 19, 2026.
How to read this chart
60‑month range R22.38 – R40.81 · fair‑value band R18.01 – R30.01 · the R32.20 price screens above the R24.01 fair value. Dashed = 300-day average. As of Jul 19, 2026.
Analysis
Dis-Chem Pharmacies Limited (DCP) currently trades at R32.20, while our model-based Fair Value estimate is R24.01, implying the stock looks roughly 25.4% overvalued today. The Quality Score stands at 55/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Dis-Chem Pharmacies Limited generated revenue of 42.8B ZAR at a net margin of 2.3%. Revenue grew 9.9% year over year. It earns a return on equity of 19.0%. Net debt stands at 6.1B ZAR. Fundamentals as of Jul 19, 2026
Our scenario range runs from R18.01 (bear case) to R30.01 (bull case); at R32.20, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at -15% fair-value upside, at -25%, DCP screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (R29.42) versus Asset-Based (R4.42). Highest evidence: Growth DCF (80).
Notify me when DCP reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 19, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 55 · Market factors (momentum, volatility) 43
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Dis-Chem Pharmacies Limited, together with its subsidiaries, engages in the retail and wholesale of healthcare products and pharmaceuticals in South Africa. The company operates through two segments, Retail and Wholesale.
Full company description
Dis-Chem Pharmacies Limited, together with its subsidiaries, engages in the retail and wholesale of healthcare products and pharmaceuticals in South Africa. The company operates through two segments, Retail and Wholesale. It owns and operates a chain of retail stores that offers various products, including dispensary, personal care and beauty, healthcare and nutrition, baby care, and other products. The company also provides pharmaceutical, health, and front shop products in the wholesale market. In addition, it offers customer loyalty programs. The company was founded in 1978 and is headquartered in Midrand, South Africa.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Dis-Chem Pharmacies Limited reported revenue of R42.8B in FY2026 versus R30.4B in FY2022, a compound +8.9%/yr. Reported net income was R979M in FY2026, compounding +3.5%/yr from FY2022.
of which total revenue +11.3 pp · buybacks/dilution −0.2 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
DCP screens 25% overvalued. Compare with JD Health International Inc →
Peer Group
Pharmaceutical Retailers · 62 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Pharmaceutical Retailers median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JD Health International Inc 6618 | HK$39.20 | HK$33.28 | -15% |
| Raia Drogasil S.A RADL3 | R$18.20 | R$15.58 | -14% |
| Yifeng Pharmacy Chain Co 603939 | ¥23.43 | ¥29.07 | +24% |
| DaShenLin Pharmaceutical Group 603233 | ¥18.23 | ¥23.86 | +31% |
| Corporativo Fragua, S.A. FRAGUAB | 463.00 MXN | 821.18 MXN | +77% |
| LBX Pharmacy Chain Joint Stock Company 603883 | ¥12.74 | ¥10.57 | -17% |
| MedPlus Health Services Limited MEDPLUS | ₹690.20 | ₹379.25 | -45% |
| Yixintang Pharmaceutical Group 002727 | ¥11.46 | ¥9.45 | -18% |
| Anhui Huaren Health Pharmaceutical Co 301408 | ¥14.40 | ¥10.05 | -30% |
| Apotea AB APOTEA | kr 74.75 | kr 43.95 | -41% |
Compare Dis-Chem Pharmacies Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Dis-Chem Pharmacies Limited (DCP) overvalued or undervalued?
What is the fair value of DCP?
What is the quality score of DCP?
What is the revenue of Dis-Chem Pharmacies Limited (DCP)?
What is the net profit margin of DCP?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Dis-Chem Pharmacies Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.